A Study That Correlates The Diversity Of Micro-Organisms In Rectum Of Rectal Cancer Patients With The Clinical And Pathological Variables Of The Patient.
Not Applicable
- Conditions
- Health Condition 1: C20- Malignant neoplasm of rectum
- Registration Number
- CTRI/2020/10/028762
- Lead Sponsor
- Regional Cancer CentreTrivandrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Diagnosis was confirmed by biopsy and histologic analysis
Exclusion Criteria
1. Intestinal obstruction
2. Received Bowel preparation within past 14 days
3. Patients received preoperative chemotherapy or radiation therapy
4. Known lactose intolerance
5. Immunodeficiency
6. Inflammatory bowel disease
7. Received antibiotics with in past 3 months before sample collection
8. Evidence of infection
9. Probiotics or prebiotics usage within 2 weeks
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link rectal microbiota diversity to malignant neoplasm of the rectum in CTRI/2020/10/028762?
How does metagenomic analysis of rectal microbiota inform potential therapeutic targets for rectal cancer?
What clinical and pathological variables correlate with specific microbial biomarkers in rectal cancer patients?
Are there adverse events associated with microbiota modulation in rectal cancer treatment strategies?
How does the rectal microbiome profile compare to other gastrointestinal cancers in terms of therapeutic implications?